On January 7, Erasca’s general counsel and corporate secretary, Garner Ebun, exercised options on 120,000 shares and immediately sold them in the open market for gross proceeds of $670,812, as disclosed in a Form 4 filing. This transaction reduced Ebun’s direct common stock holdings from 145,076 shares to 25,076 shares, representing an 82.7% decline in direct ownership. The exercise price and sale price were both based on a weighted average of $5.59 per share. Following the sale, Ebun retains 360,000 stock options (vested and unvested), preserving potential for further exercises and monetization. Investors should note that this was not a gift or indirect transfer, but an exercise under a Rule 10b5-1 plan established in June 2024, underscoring that the sale was pre-planned rather than discretionary. Over the past year, the stock has rallied 189.8%, suggesting the sale captured significant unrealized gains during a period of notable appreciation.

Erasca reported encouraging early clinical data for its lead asset ERAS-0015 in the AURORAS-1 Phase 1 trial, with two confirmed and one unconfirmed partial responses observed at an 8 mg once-daily dose, and additional unconfirmed responses at higher dose levels. No dose-limiting toxicities were reported, and adverse events were predominantly low grade, while pharmacokinetics demonstrated linear exposure across doses. ERAS-0015 monotherapy data are expected in H1 2026, with expansion and combination cohorts slated for H2 2026 and additional readouts in 2027. For ERAS-4001, the BOREALIS-1 Phase 1 trial is progressing as planned, targeting KRAS-mutant solid tumors, with initial monotherapy data anticipated in H2 2026 and expansion cohorts in 2027. As of November 2025, Erasca held $362 million in cash, projected to fund operations into the second half of 2028, while quarterly net losses narrowed year over year. Key upcoming catalysts include Phase 1 data readouts, balance sheet durability assessments, and validation of early efficacy signals in larger patient cohorts.